RxDoctor Payments Data

Wei Chuan Wang, MD

Retina Specialist · Green Bay, WINPI 1932218005

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,725 of the $2,800 with a category attached, or 61.6%. 12 manufacturers reported payments, led by Cardinal Health 108 LLC at 56.3% of the total. Reporting peaked in 2020 at $1,640 and has fallen 98.2% since, to $30 in 2025.

$2,800in general payments, 2019–2025

Across 38 payments — averaging $73.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardinal Health 108 LLC$2K
  • Regeneron Healthcare Solutions, Inc.$616
  • Cardinal Health 110 LLC$150
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$112
  • Alimera Sciences, Inc.$78
  • Bausch & Lomb Americas Inc.$75
  • plus $193 from 6 others

What the payments were for

  • Consulting fees$1,72562%
  • Food & beverage$1,04337%
  • Education$321%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,800 in reported general payments places this provider in the 70th percentile of 24 retina specialist providers in Wisconsin.

See all retina specialist providers in Wisconsin

Medicare billing

Part B allowed, 2024
$1,799,496
Medicare patients
549
Services billed
16,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium25$8,267
Prednisolone Acetate197$5,566
CombiganBrimonidine Tartrate/Timolol17$4,102
Latanoprost113$1,238
Timolol Maleate68$581
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$517
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat35$369
ErythromycinErythromycin Base20$214
Brimonidine Tartrate19$195
Dorzolamide Hcl11$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$112$8,26725 claims
AbbVieCombigan$50$4,10217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 24 retina specialist providers in Wisconsin.

Other retina specialist in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →